Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)

This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the treatment of patients with advanced solid malignancies or non-Hodgkin's lymphoma (NHL).
Not Available
Phase I
Adults
Not Available
Not Available
Not Available
National
Vanderbilt University
06-08-2016
Treatment
VICCPHI1616
NCT02702492

Eligibility

18 Years
BOTH
NO
Inclusion Criteria:

Inclusion Criteria: Patients must meet all of the following inclusion criteria to be eligible to enroll in this study. 1. Written informed consent obtained prior to any screening procedures and in accordance with federal, local, and institutional guidelines. 2. Age ? 18 years. 3. Patients with advanced solid malignancies or NHL. 4. Patients must have a site of disease amenable to biopsy and be a candidate for biopsy according to the treating institution's guidelines. 5. Dose Escalation Phase: Patients will be enrolled according to their NAPRT1 status at a ratio of 2:1 (NAPRT1 negative:NAPRT1 positive). The NAPRT1 status must be determined prior to enrollment based on evaluation of a fresh tumor biopsy or archival tissue prior to screening. 6. Life expectancy of ? 3 months. Exclusion Criteria: Patients meeting any of the following exclusion criteria are not eligible to enroll in this study. 1. Time since the last prior therapy for treatment of advanced solid malignancies or NHL**: 1. Radiation, chemotherapy, immunotherapy or any other anticancer therapy, including investigational anti-cancer therapy ? 2 weeks prior to C1D1. 2. Palliative steroids for disease related symptoms

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: